Journal Article

<i>In vitro</i> activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of <i>Mycobacterium kansasii</i>

Remedios Guna, Carlos Muñoz, Victoria Domínguez, Ángeles García-García, Jorge Gálvez, Jesús-Vicente de Julián-Ortiz and Rafael Borrás

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 55, issue 6, pages 950-953
Published in print June 2005 | ISSN: 0305-7453
Published online April 2005 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dki111
In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care

GO

Show Summary Details

Preview

Objectives: To compare the activity of linezolid with a range of drugs used in the treatment of Mycobacterium kansasii infections.

Results: The percentages of resistant isolates against isoniazid, rifampicin and ethambutol were 2.9%, 1.9% and 2.9%, respectively. All isolates were susceptible to clarithromycin and moxifloxacin both with MIC90 values of 0.125 mg/L. Linezolid was active against all isolates with MIC50 and MIC90 values of 0.5 and 1 mg/L, respectively, both below the susceptibility breakpoint established for mycobacteria.

Conclusion: Linezolid, clarithromycin or moxifloxacin, could be used as alternative drugs for treatment of infections due to rifampicin-resistant isolates as well as short-course or intermittent therapy of M. kansasii lung disease.

Keywords: non-tuberculous mycobacteria; antimycobacterial agents; broth microdilution method

Journal Article.  2592 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.